PMID- 25382436
OWN - NLM
STAT- MEDLINE
DCOM- 20170131
LR  - 20191210
IS  - 1099-1611 (Electronic)
IS  - 1057-9249 (Print)
IS  - 1057-9249 (Linking)
VI  - 24
IP  - 9
DP  - 2015 Sep
TI  - Prostate cancer survivors' beliefs about screening and treatment decision-making 
      experiences in an era of controversy.
PG  - 1073-9
LID - 10.1002/pon.3721 [doi]
AB  - OBJECTIVE: Controversy about the costs and benefits of screening and treatment of 
      prostate cancer (PCa) has recently intensified. However, the impact of the debate 
      on PCa patients has not been systematically studied. METHODS: We assessed 
      knowledge of, and attitudes toward, the U.S. Preventive Services Task Force's 
      (USPSTF) May 2012 recommendation against PSA-based screening among men diagnosed 
      with clinically localized PCa, and tested whether exposure to the recommendation 
      and associated controversy about overtreatment of PCa predicted treatment 
      decisional conflict, affected treatment choice, or increased regret about PSA 
      testing. RESULTS: Accurate knowledge of the USPSTF recommendation was uncommon 
      (19.1%). Attitudes toward the recommendation were negative, and the vast majority 
      (86.5%) remained highly supportive of annual PSA testing in men >/=50. Although 
      exposure to the recommendation and controversy about treatment was associated 
      with lower enthusiasm for screening and treatment, it was not associated with 
      treatment decisions, or greater decisional-conflict, or regret. CONCLUSIONS: 
      Findings may alleviate concern that exposure to PSA-based screening and 
      overtreatment controversies has adversely affected recent cohorts of PCa 
      patients. However, patients remain highly supportive of PSA-based screening. As 
      survivor anecdotes often influence people's medical decisions, it is important to 
      appreciate the scale of opposition to the new recommendation.
CI  - Copyright (c) 2014 John Wiley & Sons, Ltd.
FAU - Orom, Heather
AU  - Orom H
AD  - Community Health and Health Behavior, University at Buffalo, 3435 Main St., 
      Buffalo, NY, 14214, USA.
FAU - Underwood, Willie 3rd
AU  - Underwood W 3rd
AD  - Urologic Oncology, Roswell Park Cancer Institute, Elm & Carlton, Buffalo, NY, 
      14263, USA.
FAU - Homish, D Lynn
AU  - Homish DL
AD  - Community Health and Health Behavior, University at Buffalo, 3435 Main St., 
      Buffalo, NY, 14214, USA.
FAU - Kiviniemi, Marc T
AU  - Kiviniemi MT
AD  - Community Health and Health Behavior, University at Buffalo, 3435 Main St., 
      Buffalo, NY, 14214, USA.
FAU - Homish, Gregory G
AU  - Homish GG
AD  - Community Health and Health Behavior, University at Buffalo, 3435 Main St., 
      Buffalo, NY, 14214, USA.
FAU - Nelson, Christian J
AU  - Nelson CJ
AD  - Memorial Sloan-Kettering Cancer Center, 641 Lexington Ave, New York, NY, 10022, 
      USA.
FAU - Schiffman, Zvi
AU  - Schiffman Z
AD  - Houston Metro Urology P. A., 4223 Richmond Ave, Houston, TX, 77027, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA152425/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20141110
PL  - England
TA  - Psychooncology
JT  - Psycho-oncology
JID - 9214524
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Conflict, Psychological
MH  - *Decision Making
MH  - Dissent and Disputes
MH  - Early Detection of Cancer/*psychology
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Practice Guidelines as Topic
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms/psychology/*therapy
MH  - Survivors/*psychology/statistics & numerical data
MH  - United States
PMC - PMC5514549
MID - NIHMS766877
OTO - NOTNLM
OT  - cancer screening
OT  - decision making
OT  - oncology
OT  - prostate cancer
OT  - prostate-specific antigen (PSA)
OT  - survivorship
COIS- Conflict of interest None of the authors of this manuscript has any actual, 
      perceived, or potential conflicts of interest that would interfere with the 
      accurate reporting of the results.
EDAT- 2014/11/11 06:00
MHDA- 2017/02/01 06:00
PMCR- 2017/07/18
CRDT- 2014/11/11 06:00
PHST- 2014/05/13 00:00 [received]
PHST- 2014/09/09 00:00 [revised]
PHST- 2014/10/15 00:00 [accepted]
PHST- 2014/11/11 06:00 [entrez]
PHST- 2014/11/11 06:00 [pubmed]
PHST- 2017/02/01 06:00 [medline]
PHST- 2017/07/18 00:00 [pmc-release]
AID - 10.1002/pon.3721 [doi]
PST - ppublish
SO  - Psychooncology. 2015 Sep;24(9):1073-9. doi: 10.1002/pon.3721. Epub 2014 Nov 10.